Mark J. Alles
Chairman and Chief Executive Officer
Mark J. Alles became Chief Executive Officer as of March 1, 2016 and joined the Celgene Board of Directors in February 2016. The role of Chairman was added in February 2018.
Mr. Alles served as President and Chief Operating Officer from August 2014 until February 2016, Executive Vice President and Global Head of Hematology & Oncology from December 2012 until July 2014 and was also Celgene’s Chief Commercial Officer. Mr. Alles joined Celgene in April 2004 and was Vice President, Global Hematology Marketing until March 2009 when he was promoted to President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Before joining Celgene, he was Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals and served in other senior commercial management roles at Aventis (Rh?ne-Poulenc Rorer) from 1993-2004.
Mr. Alles began his thirty-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He is a member of the Board of Directors of the Pharmaceutical Manufacturers of America (PhRMA). Mr. Alles earned his B.S. degree from Lock Haven University of Pennsylvania and served as a Captain in the United States Marine Corps?.
Richard W. Barker, D.Phil., OBE
Chairman of the Health Innovation Network of South London
Richard W. Barker, D.Phil., OBE, was elected to the Celgene Board of Directors in January 2012 and is a member of the Audit Committee.
Dr. Barker was formerly Director General of the Association of the British Pharmaceutical Industry (ABPI), a pharmaceutical industry trade association in the United Kingdom, from 2004 to 2011, and served on the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and as a Council Member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Dr. Barker is currently Chairman of the Health Innovation Network of South London, UK and Chairman of International Health Partners, a UK charity providing donated medicines to crisis situations, and serves as a Director of Image Analysis Group, a company applying advanced algorithmic analysis to medical images. Dr. Barker received a B.A. from the University of Oxford.
Chief Executive Officer of GRAIL, Inc.
Hans Bishop was elected to the Celgene Board of Directors in April 2018.
Mr. Bishop has served as the Chief Executive Officer of GRAIL, Inc. a private healthcare company, since June 2019, and served as a member of GRAIL’s board of directors since August 2016. Mr. Bishop has also been the co-founder and Executive Chairman of Sana Biotechology, Inc., a private biotechnology company, since January 2019. He was a co-founder and served as President and CEO and was a member of its Board of Directors of Juno Therapeutics from 2013 until Juno was acquired by Celgene in March 2018. Mr. Bishop previously served as a member of the Board of Directors of Avanir Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company from May 2012 until January 2015, when Avanir was sold to Otsuka Pharmaceuticals Co., Ltd. Mr. Bishop served as an Executive in Residence at Warburg Pincus, a global private equity firm with significant investment experience in the pharmaceutical and healthcare industries.
Prior to this, he acted as Executive Vice President and Chief Operating Officer for Dendreon, a publicly-traded biotechnology company that develops immunotherapy products used in cancer treatment. He has served as President of the Specialty Medicine business at Bayer Healthcare Pharmaceuticals Inc., Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals. Mr. Bishop previously held various positions at Glaxo Wellcome and SmithKlineBeecham. Mr. Bishop serves as Chairman of the Board of Lyell Immunopharma, Inc. and serves as a member of the Board of Directors of Agilent Technologies, Inc. He earned a B.Sc. in chemistry from Brunel University in London.
Michael W. Bonney
Executive Chair of the Board of Kaleido Biosciences
Michael W. Bonney was elected to the Celgene Board of Directors in April 2015. Mr. Bonney is a member of the Executive Committee and the Nominating, Governance and Compliance Committee.
Mr. Bonney is currently the Executive Chair of the Board of Kaleido Biosciences, Inc., having served as Chief Executive Officer and Chairman from June 2017 to August 2018. From January to July 2016, Mr. Bonney was a Partner of Third Rock Ventures, LLC. Previously, Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. (which was acquired by Merck & Co., Inc. in January 2015) from June 2003 until December 2014.
Prior to Cubist, Mr. Bonney was Vice President, Sales and Marketing at Biogen, Inc. Prior to joining Biogen, Mr. Bonney spent eleven years at Zeneca Pharmaceuticals, in a range of commercial, operating and strategic roles, ending his career there as National Business Director. Mr. Bonney chairs the Board of Directors of Alnylam Pharmaceuticals, Inc. and Magenta Therapeutics. He also serves as a member of the Board of Directors of Sarepta Therapeutics Inc. and Syros Pharmaceuticals. Mr. Bonney previously served as a member of the Board of Directors of Global Blood Therapeutics, Inc. and NPS Pharmaceuticals, Inc. Mr. Bonney received a B.A. in Economics from Bates College and now Chairs its Board of Trustees.
Michael D. Casey
Independent Lead Director
Michael D. Casey was elected to the Celgene Board of Directors in August 2002 and has been the Lead Independent Director since June 2007. Mr. Casey is the Chairman of the Nominating, Governance and Compliance Committee, a member of the Executive Committee, and a member of the Management Compensation and Development Committee.
From September 1997 to February 2002, Mr. Casey served as the Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc. In December 1996, he was appointed President of the retail and specialty products division of Schein Pharmaceutical, Inc. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey also served as a director of Abaxis Inc., Allos Therapeutics, Inc. AVI BioPharma and Durect Corporation.
Carrie S. Cox
Chairman of the Board of Directors, Humacyte, Inc.
Carrie S. Cox was elected to the Celgene Board of Directors in December 2009 and is a member of the Management Compensation and Development Committee.
Ms. Cox currently serves as the Chairman of the Board of Directors of Humacyte, Inc., a privately-held regenerative medicine company primarily focused on developing novel human tissue-based investigational products for applications in regenerative medicine and vascular surgery. From 2010 until June 2018, Ms. Cox served as Chairman and CEO of Humacyte, Inc. Ms. Cox served as Executive Vice President of Schering-Plough Corporation and President of Schering-Plough’s Global Pharmaceutical Business from 2003 until 2009, when Schering-Plough merged with Merck & Co., Inc. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s pharmaceutical business until its merger with Pfizer Inc. in 2003. Ms. Cox serves as Chairman of the Board of Array BioPharma, Inc. and electroCore Inc. and is a member of the Board of Directors of Texas Instruments and Cardinal Health, Inc. Ms. Cox is a graduate of the Massachusetts College of Pharmacy.
Michael A. Friedman, M.D.
Emeritus Chief Executive Officer, City of Hope
Michael A. Friedman, MD, was elected to the Celgene Board of Directors in February 2011 and is a member of the Nominating, Governance and Compliance Committee.
Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization’s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director’s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration (FDA), later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004, Dr. Friedman has served on the Independent Citizens’ Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California’s stem cell research effort. Dr. Friedman serves as a member of the Board of Directors of Institutional Surgical, Inc. and MannKind Corporation. Dr. Friedman previously served as a member of the Board of Directors of Smith & Nephew plc. He is also a member of the Board of Trustees of Tulane University. Dr Friedman received a B.A. from Tulane University and a M.D. in Medicine from the University of Texas.
Julia A. Haller, M.D.
Ophthalmologist-in-Chief, Wills Eye Hospital
Julia Haller, M.D., was elected to the Celgene Board of Directors in October 2015 and is a member of the Audit Committee.
Dr. Haller has served as the Ophthalmologist-in-Chief of the Wills Eye Hospital in Philadelphia since 2007, where she holds the William Tasman, M.D. Endowed Chair. She serves as Professor and Chair of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals, and is Co-Director of the Wills Vision Research Center at Jefferson. In 1986, Dr. Haller served as the first female Chief Resident at the Wilmer Eye Institute at Johns Hopkins and later joined the Johns Hopkins faculty. She was named the inaugural Katharine Graham Professor of Ophthalmology in 2002, and the inaugural Robert Bond Welch, M.D. Professor of Ophthalmology in 2006. In 2007, Dr. Haller assumed leadership of Wills Eye Hospital. She received her A.B. from Princeton University magna cum laude and her M.D. from Harvard Medical School.
Patricia Hemingway Hall
Former Chief Executive Officer, Health Care Service Corporation (HCSC)
Patricia “Pat” Hemingway Hall was elected to the Celgene Board of Directors in April 2018 and is a member of the Audit Committee.
From 2008 until her retirement in 2015, Ms. Hemingway Hall served as President and CEO of Health Care Service Corporation (HCSC), a mutual health insurance company. Previously, Ms. Hemingway Hall held senior leadership positions at HCSC since 1993, including President and Chief Operating Officer from 2007 to 2008, Executive Vice President of Internal Operations from 2006 to 2007, President of Blue Cross and Blue Shield of Texas, a division of HCSC, from 2001 to 2005 and Senior Vice President from 1998 to 2001. Prior to joining HCSC, Ms. Hemingway Hall held senior positions with several healthcare and health insurance companies and started her career as a critical care nurse. She currently serves as a member of the Board of Directors of Cardinal Health, Inc., Haliburton Company and Manpower Group. She earned a MPH in Health Planning and Administration from the University of Michigan and a Bachelor of Science in nursing from Michigan State University.
James J. Loughlin
Retired Partner KPMG, LLP
James J. Loughlin was elected to the Celgene Board of Directors in January 2007. Mr. Loughlin is Chairman of the Audit Committee and a member of the Management Compensation and Development Committee.
Mr. Loughlin served as the National Director of the Pharmaceuticals Practice at KPMG LLP (KPMG), and a five-year term as member of the Board of Directors of KPMG. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. Mr. Loughlin serves as a member of the Board of Directors of Edge Therapeutics, Inc. Mr. Loughlin received his B.S. in accounting from St. Peter’s University and is a certified public accountant.
Ernest Mario, Ph.D.
Chairman of the Board of Soleno Therapeutics, Inc.
Ernest Mario, Ph.D. was elected to the Celgene Board of Directors in August 2007. Dr. Mario is Chairman of the Management Compensation and Development Committee, a member of the Nominating, Governance and Compliance Committee, and a member of the Executive Committee.
Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario also serves as Chairman of the Board of Soleno Therapeutics, Inc. (formerly Capnia, Inc.) and as a Director of Eyenovia Inc. and Kindred Biosciences, Inc. He previously served as a member of the Board of Directors of Boston Scientific Corporation, Chimerix Inc., Maxygen Inc., Tonix Pharmaceuticals Holding Corp., VIVUS Inc. and XenoPort Inc. He serves as an advisor to The Ernest Mario School of Pharmacy at Rutgers University. In 2007, Dr. Mario was awarded the Remington Medal by the American Pharmacists Association, pharmacy’s highest honor. Dr. Mario received his B.S. in Pharmacy from Rutgers University and an M.S. and a Ph.D. in Physical Sciences from the University of Rhode Island.
John H. Weiland
Former President and Chief Operating Officer, C. R. Bard, Inc.
John Weiland was elected to the Celgene Board of Directors in February 2018 and is a member of the Audit Committee.
Mr. Weiland was President and Chief Operating Officer of C. R. Bard, Inc. (Bard) from 2003 until 2017 when Bard was acquired by Becton Dickinson and Company. He was elected to Bard’s Board of Directors in 2005 and became Vice Chairman of the Board in 2016. Mr. Weiland joined Bard in 1996 and prior to becoming President and COO, he held the position of Group President. Prior to Bard, Mr. Weiland held the position of Senior Vice President North America Group for Dentsply International. Mr. Weiland started his career at Baxter/American Hospital Supply Corporation in 1977. He rose through numerous managerial positions to become Vice President and General Manager of the Scientific Products Biomedical Division. In 1989, he became President and Chief Executive Officer of Pharmacia Diagnostics, a division of Pharmacia AB Uppsala Sweden. In addition to his professional activities, John is actively involved in civic affairs. Mr. Weiland was the recipient of the distinguished Horatio Alger Award. He serves as a member of the Board of Directors of Cardinal Health, Inc. and the Horatio Alger Association and previously served as a member of the Board of Directors of West Pharmaceutical Services, Inc. Mr. Weiland graduated from DeSales University with a B.S. degree and earned an M.B.A. degree from New York University.